Heart Test Laboratories Income Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Year Ending	TTM	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021	Apr 30, 2020
Revenue	0.02	0.01	0.01	0.03	0.06
Revenue Growth (YoY)	100.02%	-64.17%	-43.86%	-60.11%	-
Cost of Revenue	0.01	0	0.01	0.01	0.05
Gross Profit	0.01	0	0.01	0.01	0.02
Selling, General & Admin	3.67	3.65	1.71	0.87	1.8
Research & Development	2.37	2.46	3	1.71	2.04
Operating Expenses	6.04	6.12	4.72	2.58	3.84
Operating Income	-6.02	-6.11	-4.71	-2.57	-3.82
Interest Expense / Income	0.37	0.24	0.37	0.13	0
Other Expense / Income	-0	-0	-0.25	-0.25	-0.01
Pretax Income	-6.39	-6.35	-4.83	-2.45	-3.81
Net Income	-6.39	-6.35	-4.83	-2.45	-3.81
Shares Outstanding (Basic)	1	0	0	0	0
Shares Outstanding (Diluted)	1	0	0	0	0
Shares Change	552.76%	139.56%	0.15%	-	-
EPS (Basic)	-48.00	-80.00	-145.00	-74.00	-115.00
EPS (Diluted)	-48.00	-80.00	-145.00	-74.00	-115.00
Free Cash Flow	-6.42	-5.79	-3.65	-2.45	-3.83
Free Cash Flow Per Share	-11.93	-72.85	-109.86	-74.02	-115.63
Gross Margin	67.31%	45.71%	45.11%	58.35%	27.61%
Operating Margin	-32390.53%	-118698.33%	-32765.60%	-10030.18%	-5949.00%
Profit Margin	-34362.39%	-123384.27%	-33592.57%	-9577.29%	-5937.99%
Free Cash Flow Margin	-34509.47%	-112463.79%	-25367.54%	-9580.56%	-5970.25%
EBITDA	-6	-6.08	-4.43	-2.29	-3.74
EBITDA Margin	-32251.55%	-118139.83%	-30822.20%	-8928.70%	-5834.16%
Depreciation & Amortization	0.03	0.03	0.03	0.03	0.06
EBIT	-6.02	-6.11	-4.46	-2.32	-3.81
EBIT Margin	-32388.74%	-118662.45%	-31007.03%	-9059.98%	-5933.61%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).